Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
128.7 USD | -0.43% | -1.19% | +18.17% |
02:36pm | US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine | RE |
May. 13 | Merck: phase 3 trial in melanoma halted | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.17% | 327B | |
+30.93% | 682B | |
+30.35% | 586B | |
-3.49% | 364B | |
+4.07% | 285B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+8.22% | 165B | |
-1.62% | 161B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Jefferies Adjusts Merck & Company Price Target to $150 From $145